



Mouse anti-EBOV GP monoclonal antibody (13C6)

Catalog #: 0201-024

Lot #: 2007007

Venezuelan equine encephalitis virus Immunogen: replicons encoding Ebola Virus (EBOV) glycoprotein (GP) were used to generate the original mouse monoclonal antibody.

Description: Protein A purified mouse monoclonal antibody reactive to EBOV GP.

Supplied: 100 µg is supplied in PBS at a concentration of 4.192 mg/mL. No preservative is added.

Clonality: Murine IgG2a

Relevance: The antibody can be used for detection of EBOV GP in ELISA. A mixture of three anti-EBOV GP chimeric antibodies (c13C6, c6D8 and h13F6) was protective against lethal challenge in a nonhuman primate study (Olinger *et al*. PNAS 2012, vol. 109, no. 44, 18030-18035).

Recommended Dilutions:

ELISA: Assay-dependent dilution

WB: Not recommended because this antibody recognizes a conformational epitope.

Storage: 2-3 weeks +4°C, ≤-20°C long term

Cross Reactivity: Cross-reactivity was observed against Sudan Virus (SUDV) GP. No cross-reactivity against Marburg Virus (MARV) GP.

Related Products:

IBT provides a wide array of anti-filovirus specific antibodies, recombinant proteins and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

ELISA Data:

Antibody (μg/mL)	Coating Antigen: VLP @ 10 µg/mL		
	EBOV	SUDV	MARV
10.0000	3.528	1.809	0.053
3.1623	3.529	1.406	0.049
1.0000	3.310	1.022	0.057
0.3162	3.291	0.632	0.062
0.1000	2.852	0.303	0.057
0.0316	1.949	0.146	0.077
0.0100	0.936	0.079	0.059
0.0032	0.378	0.070	0.063
0.0010	0.185	0.058	0.073
0.0003	0.108	0.062	0.096
0.0001	0.072	0.084	0.060
	OD 650		

Antibody (μg/mL)	Coating Antigen: rGP∆TM @ 1 µg/mL			
	EBOV	SUDV	MARV	
10.0000	3.581	2.690	0.055	
3.1623	3.500	2.272	0.037	
1.0000	3.374	1.585	0.068	
0.3162	3.243	0.852	0.070	
0.1000	2.814	0.371	0.066	
0.0316	2.144	0.166	0.037	
0.0100	1.221	0.089	0.086	
0.0032	0.541	0.062	0.069	
0.0010	0.234	0.058	0.093	
0.0003	0.165	0.055	0.070	
0.0001	0.093	0.058	0.070	
	OD 650			

Virus-like particles and recombinant GP proteins without the transmembrane domain (rGPΔTM) were diluted in PBS to 10 µg/mL and 1 µg/mL, respectively. m13C6 was serially diluted semi-log from 10 µg/mL and incubated on the coated plates. Washed plates were detected with antimouse IgG-HRP conjugate and TMB substrate. OD650 is reported above.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.

Copyright 2020. Integrated BioTherapeutics, Inc. All rights reserved.